After clearing bubbles, check your dose marking again
A total of 577 patients were randomly assigned (1:1:1) to receive once-weekly dulaglutide (1.5 mg), once-weekly dulaglutide (0.75 mg), or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks
For more information, visit www.hims.com/weight-loss or www.forhers.com/weight-loss Assets Download Contact Abby Reisinger-Moley [email protected] 1 Access to Zepbound and Foundayo does not imply a partnership or affiliation with Eli Lilly and Company
The field is rapidly moving beyond single-target GLP-1 agonism: dual and triple agonists, combining GLP-1 with receptors for GIP and/or glucagon, are designed to produce larger weight loss and beneficial metabolic effects
ALSO READ: Food Systems Largest Violators Of Planetary Limits: 2025 Eat-lancet Commission 9
Both options are backed by Nooms behavior change tools and clinical care teamsso you get the guidance you need, no matter your path
